Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Sharma, S; Babiker, A G; Emery, S; Gordin, F M; Lundgren, J D; Neaton, J N; Bakowska, E; Schechter, M; Wiselka, M J; Wolff, M J

Sharma, S; Babiker, A G; Emery, S; Gordin, F M; Lundgren, J D; Neaton, J N; Bakowska, E; Schechter, M; Wiselka, M J; Wolff, M J.

Affiliation

Sharma S; Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.

HIV Med ; 16 Suppl 1: 30-6, 2015 Apr.

Article in En | MEDLINE | ID: mdl-25711321

Subject(s)

Anti-Retroviral Agents/therapeutic use; Antiretroviral Therapy, Highly Active/methods; Demography; HIV Infections/drug therapy; Adult; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections/immunology; HIV Infections/pathology; Humans; Male; Middle Aged; Time Factors; Treatment Outcome

Key words

HIV; START trial; clinical trial; when to start antiretroviral therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: HIV Infections / Demography / Antiretroviral Therapy, Highly Active / Anti-Retroviral Agents Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Year: 2015 Type: Article

Fulltext

XML

PubMed Links

Search on Google